181 related articles for article (PubMed ID: 28024916)
21. Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells.
Hongrapipat J; Kopecková P; Liu J; Prakongpan S; Kopecek J
Mol Pharm; 2008; 5(5):696-709. PubMed ID: 18729468
[TBL] [Abstract][Full Text] [Related]
22. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.
Chu TW; Zhang R; Yang J; Chao MP; Shami PJ; Kopeček J
Theranostics; 2015; 5(8):834-46. PubMed ID: 26000056
[TBL] [Abstract][Full Text] [Related]
23. [One amino acid mutation in an anti-CD20 antibody fragment that affects the yield bacterial secretion and the affinity].
Liu YX; Xiong DS; Fan DM; Shao XF; Xu YF; Zhu ZP; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2003 May; 19(3):272-6. PubMed ID: 15969005
[TBL] [Abstract][Full Text] [Related]
24. [High level expression of chimeric antibody fragment F(ab')2 directed against CD20 in Escherichia coli].
Xiong DS; Zheng MJ; Liu YX; Xu YF; Wang JH; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2004 Sep; 20(5):673-8. PubMed ID: 15973988
[TBL] [Abstract][Full Text] [Related]
25. [Preclinical study of apoptosis of B-NHL cell lines induced by anti-CD20 monoclonal antibody].
Zhang HY; Chen HT; Guan ZZ; Huang Y; Zhang X; Lin TY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):883-7. PubMed ID: 19698222
[TBL] [Abstract][Full Text] [Related]
26. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
28. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
29. Broadening and Enhancing Functions of Antibodies by Self-Assembling Multimerization at Cell Surface.
Li L; Wang J; Li Y; Radford DC; Yang J; Kopeček J
ACS Nano; 2019 Oct; 13(10):11422-11432. PubMed ID: 31553883
[TBL] [Abstract][Full Text] [Related]
30. Design of smart HPMA copolymer-based nanomedicines.
Yang J; Kopeček J
J Control Release; 2016 Oct; 240():9-23. PubMed ID: 26437260
[TBL] [Abstract][Full Text] [Related]
31. Preparation and biological evaluation of polymerizable antibody Fab' fragment targeted polymeric drug delivery system.
Lu ZR; Shiah JG; Kopecková P; Kopecek J
J Control Release; 2001 Jul; 74(1-3):263-8. PubMed ID: 11489505
[TBL] [Abstract][Full Text] [Related]
32. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
33. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
35. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis.
Zhou Z; Zhang J; Zhang Y; Ma G; Su Z
Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095
[TBL] [Abstract][Full Text] [Related]
36. Design of novel bioconjugates for targeted drug delivery.
Lu ZR; Shiah JG; Sakuma S; Kopecková P; Kopecek J
J Control Release; 2002 Jan; 78(1-3):165-73. PubMed ID: 11772458
[TBL] [Abstract][Full Text] [Related]
37. [Ceramide participates in cell programmed death induced by Type II anti-CD20 mAb].
Huang Y; Wu S; Zhang Y; Zi Y; Yang M; Guo Y; Zhang L; Wang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 40(12):1292-7. PubMed ID: 26739069
[TBL] [Abstract][Full Text] [Related]
38. Polymerizable Fab' antibody fragments for targeting of anticancer drugs.
Lu ZR; Kopecková P; Kopecek J
Nat Biotechnol; 1999 Nov; 17(11):1101-4. PubMed ID: 10545917
[TBL] [Abstract][Full Text] [Related]
39. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.
Zhang N; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941
[TBL] [Abstract][Full Text] [Related]
40. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
